Livatag®

18 Sep, 2017

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, will host a conference call today for its shareholders at 3.00 pm CEST to comment on the main…read more →

11 Sep, 2017

Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma

Paris (France), September 11, 2017 – 8:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced top line results from the phase III ReLive trial of Livatag® (doxorubicine Transdrug™) in adult patients with…read more →

23 May, 2017

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 10th unanimous recommendation from the Data Safety Monitoring Board (DSMB), to continue without modification…read more →

10 May, 2017

Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma

USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032 Paris (France), May 10, 2017 – 6.30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology,…read more →

8 Feb, 2017

Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, wishes to clarify information regarding the ReLive trial design and conduct and, in particular, the role of its Data Safety and Monitoring…read more →

24 Jan, 2017

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

Milestone completion in line with expected preliminary outcomes mid-2017  Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the completion of enrollment in ReLive, the international Phase III clinical…read more →

21 Nov, 2016

Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 9th unanimous recommendation from the Data Safety Monitoring Board (DSMB), an independent European board of experts that monitors the safety of…read more →

4 Nov, 2016

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced encouraging results from a series of preclinical studies evaluating Livatag® interest for pancreatic cancer. Livatag® (doxorubicine Transdrug™, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically…read more →

12 Sep, 2016

Onxeo Announces First Outcomes of Livatag® Preclinical Plan

Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced Effect in Combination with Immunotherapy  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced data from 2 in vivo studies of the Livatag® preclinical plan…read more →

18 Apr, 2016

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment // DANISH TRANSLATION: Endelige data fra mekanistisk studie med Livatag® viser foretrukken affinitet for leveren, hvilket understøtter brugen til behandling af fremskreden HCC

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today reported the final data from a study aiming to confirm the mechanism…read more →

4 Apr, 2016

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

16 Mar, 2016

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting // DANISH TRANSLATION: Onxeo-poster godkendt til præsentation på årsmødet i AACR: Livatag® demonstrerer unik virkningsmekanisme

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that a poster demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the…read more →

22 Feb, 2016

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents // DANISH TRANSLATION: Onxeo udvider sine samarbejdsaftaler for at videreudvikle sit program med væsentlige aktiver inden for sjældne kræftsygdomme i kombination med immune-onkologiske stoffer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver Unit at Clinica Universidad de Navarra in Spain under the leadership of Prof. B. Sangro Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan…read more →

18 Nov, 2015

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets // DANISH TRANSLATION: Onxeo indleder omfattende strategiplan for at øge værdien af selskabets vigtigste lægemidler til behandling af sjældne kræftsygdomme

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University Hospital and Synovo’s immuno-oncology specialists  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initiation of a comprehensive strategy to explore further potential indications…read more →

5 Oct, 2015

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC — Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue the study…read more →

123